Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1

Conditions

Cholangiocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × infigratinib × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Emory University

Phase 2 Withdrawn
Gastrointestinal

Cholangiocarcinoma

NCT02706691 2019-04-16

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

University of Chicago

Phase 2 Terminated
1 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡